Precision Medicine and PET/Computed Tomography in Melanoma

Esther Mena, Yasemin Sanli, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalPET Clinics
Volume12
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Precision Medicine
medicine
Melanoma
therapy
tomography
Tomography
molecular biology
sequencing
mutations
subgroups
Immunomodulation
Therapeutics
tumors
Molecular Biology
Mutation
Neoplasms

Keywords

  • Biomarker
  • Immunotherapy
  • Melanoma
  • Molecular imaging
  • Precision oncology
  • Targeted therapy

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Precision Medicine and PET/Computed Tomography in Melanoma. / Mena, Esther; Sanli, Yasemin; Marcus, Charles; Subramaniam, Rathan M.

In: PET Clinics, Vol. 12, No. 4, 01.10.2017, p. 449-458.

Research output: Contribution to journalReview article

Mena, Esther ; Sanli, Yasemin ; Marcus, Charles ; Subramaniam, Rathan M. / Precision Medicine and PET/Computed Tomography in Melanoma. In: PET Clinics. 2017 ; Vol. 12, No. 4. pp. 449-458.
@article{66264c1a362b4f07805c484706888a6f,
title = "Precision Medicine and PET/Computed Tomography in Melanoma",
abstract = "Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.",
keywords = "Biomarker, Immunotherapy, Melanoma, Molecular imaging, Precision oncology, Targeted therapy",
author = "Esther Mena and Yasemin Sanli and Charles Marcus and Subramaniam, {Rathan M.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.cpet.2017.05.002",
language = "English (US)",
volume = "12",
pages = "449--458",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Precision Medicine and PET/Computed Tomography in Melanoma

AU - Mena, Esther

AU - Sanli, Yasemin

AU - Marcus, Charles

AU - Subramaniam, Rathan M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.

AB - Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.

KW - Biomarker

KW - Immunotherapy

KW - Melanoma

KW - Molecular imaging

KW - Precision oncology

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85023613386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023613386&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.05.002

DO - 10.1016/j.cpet.2017.05.002

M3 - Review article

C2 - 28867115

AN - SCOPUS:85023613386

VL - 12

SP - 449

EP - 458

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 4

ER -